EOLS News and Press, Evolus Inc. From 01/23/23

Australia among the largest countries in the world for aesthetic neurotoxins 1 Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the Australian Therapeutic Goods Administrati...

Oral presentation for longer duration formulation on Saturday, January 28, 2023 Investor webcast to discuss findings on Monday, January 30, 2023 Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough produc...

Shares of Evolus (NASDAQ: EOLS) were up by 27.1% for the week as of Friday afternoon, according to data provided by S&P Global Market Intelligence . The medical aesthetics company specializes in using neurotoxins as aesthetic therapies. The company's shares rose after the comp...

Evolus ( NASDAQ: EOLS ) on Wednesday announced Q4 preliminary unaudited net revenue of about $43.6M, above analysts estimate of $43.21M. ( EOLS ) is trading ~18% higher. The company said it expects 2023 net revenue to be $180M to $190M. Analysts on an average expect re...

Botox maker Evolus, Inc. ( NASDAQ: EOLS ) added ~16% on Wednesday to reach the highest level since September after the company pre-announced its Q4 and full-year results for 2022, exceeding Wall Street forecasts. Based on preliminary unaudited results, Evolus ( EOLS ) expects ...

Q4 2022 Preliminary Unaudited Net Revenue of Approximately $43.6 Million, Up 26% from Q4 2021 Full-Year 2022 Preliminary Unaudited Net Revenue of Approximately $148.6 Million, Up 49% Over 2021 2023 Net Revenue Expected to be $180 to $190 Million Projecting Profitability, P...

Second Tranche of $50 Million Now Available Until December 31, 2023, Providing Continued Financial Flexibility All Other Facility Terms and Conditions Remain Unchanged Company Continues to Expect Existing Cash to Fund Current Operations Through Breakeven Evolus, Inc. (...

Leading MedTech marketplace Pipeline Medical now provides Jeuveau® by Evolus, Inc. PR Newswire NEW BRUNSWICK, N.J. , Dec. 7, 2022 /PRNewswire/ -- Pipeline Medical , a MedTech marketplace focused on supplying pharmaceuticals and medical supplies to medica...

Evolus, Inc. (EOLS) Q3 2022 Earnings Conference Call November 08, 2022 4:30 PM ET Company Participants David Erickson – Vice President-Investor Relations David Moatazedi – President and Chief Executive Officer Sandra Beaver – Chief Financial ...

Evolus press release ( NASDAQ: EOLS ): Q3 GAAP EPS of -$0.36 in-line. Revenue of $33.9M (+27.1% Y/Y) misses by $2.12M . Reiterates Full-Year 2022 Net Revenue Guidance at Top End of $143 to $150 Million Range; ; consensus $149.88M. Company Lowers Non-GAAP O...